Skip to main content
. 2021 Aug 21;14(8):823. doi: 10.3390/ph14080823

Figure 5.

Figure 5

Mice infected with TSP-AB-03 show improved survival rate after treatment with AS101. (a), CD-1 mice were intraperitoneally injected with lethal challenges of TSP-AB-03 and treated with 1× PBS (vehicle), meropenem (MEM, 200 mg/kg/day), colistin methanesulfonate (CMS, 40 mg/kg/day) or AS101 at various dosages. Infected mouse viabilities were observed as 16.7% (1/6) for the vehicle treatment; 16.7% (1/6) for MEM; 33.3% (4/12) for CMS; 41.7% (5/12) for AS101 (1.67 mg/kg/day) and 58.3% (7/12) for AS101 (3.33 mg/kg/day). Bacterial clearance was determined using plating counts from the liver (b), kidney (c) or spleen (d) of different treated mice. Placebo: n = 3; CMS and AS101: n = 4. Data expressed as mean ± SD. ns: no significance; *, p < 0.05; **, p < 0.01; ***, p < 0.001.